Skip to main content
. 2021 Jul 13;13(1):45. doi: 10.1186/s42077-021-00162-6

Table 2.

Outcome

Group C
(n=25)
Group I
(n=25)
Tests
Mean±SD Mean±SD t/X2 P-value
Heart rate (beat/min.)
T0 98.20±7.21 96.84±3.33 0.856 0.396
T1 93.32±5.78 87.04±3.23 4.742 <0.001**
T2 86.36±5.82 78.36±3.03 6.095 <0.001**
T3 84.64±5.03 68.8±3.34 13.111 <0.001**
Urine output (ml/24 hrs.)
T0 834.44±88.50 829.60±105.17 0.176 0.861
T1 1102.48±165.75 1090.40±179.53 0.247 0.806
T2 1583.56±169.26 1684.60±169.40 2.110 0.040*
T3 1838.44±131.88 2141.96±210.83 6.103 <0.001**
cystatin c (mg/l)
T0 1.71±0.16 1.79±0.17 1.571 0.123
T1 1.57±0.14 1.42±0.15 3.653 0.002*
T2 1.36±0.12 1.14±0.13 6.421 <0.001**
T3 1.21±0.15 0.98±.12 5.615 <0.001**
eGFR (ml/min/1.73m2)
T0 44.68±3.67 44.24±3.38 0.441 0.661
T1 70.24±4.59 73.76±4.44 2.758 0.008*
T2 79.20±4.07 82.96±5.68 2.689 0.010*
T3 96.52±6.36 103.32±6.96 3.606 <0.001**
Number need HD 4(16%) 2(8%) 0.758 0.384
Vasopressor (μg/kg/min.)
T0 0.41±0.06 0.39±0.06 0.659 0.513
T1 0.36±0.03 0.35±0.03 1.161 0.252
T2 0.33±0.07 0.27±0.06 3.272 0.002*
T3 0.16±0.03 0.14±0.03 2.240 0.030*
Length of stay 12(48%) 9(36%) 0.739 0.390
Mortality 2(8%) 2(8%) 0.000 1.000

Group (C): received conventional treatment sepsis and placebo tablet, Group (I): received conventional treatment sepsis and Ivardrabine tablet, HD: hemodialysis, eGFR C :estimated glomerular filtration rate based on cystatin C, T0: baseline value, T1: day 1 after beginning of the study. T2: day 1 after beginning of the study T3: day 1 after beginning of the study